Iron status and clinical outcome in patients with coronary artery disease after coronary stenting

Gjin Ndrepepa1, Siegmund Braun, Alban Dibra

  • 1Klinik für Herz- und Kreislauferkrankungen und Institut für Laboratoriumsmedizin, Deutsches Herzzentrum München and Technische Universität München, Lazarettstrasse 36, 80636 München, Germany. ndrepepa@dhm.mhn.de

Insights

This study found no link between body iron status and major adverse cardiac events or restenosis in patients after coronary stenting. Iron levels did not impact clinical outcomes or restenosis rates in this patient group.

Area of Science:

  • Cardiology
  • Iron Metabolism
  • Biomarkers

Background:

  • Iron status is a potential factor influencing cardiovascular health.
  • No prior studies have investigated the association between iron status and outcomes following coronary stenting.
  • This research addresses a gap in understanding iron's role in post-stenting complications.

Purpose of the Study:

  • To determine if body iron status is associated with major adverse cardiac events (MACE) in patients undergoing coronary stenting.
  • To investigate the relationship between iron status and the incidence of angiographic coronary restenosis after stenting.

Main Methods:

  • A cohort of 664 patients with coronary artery disease who received coronary stents was analyzed.
  • Iron status was assessed using the soluble transferrin receptor/ferritin ratio (sTfR/ferritin ratio).
  • Patients were stratified into three groups based on sTfR/ferritin ratio tertiles to evaluate clinical outcomes and restenosis rates.

Main Results:

  • No significant difference in the cumulative incidence of MACE (death, myocardial infarction, target vessel revascularization) was observed across the three iron status groups (p=0.68).
  • Rates of angiographic restenosis at 6 months were also similar among the lower, middle, and upper tertiles of the sTfR/ferritin ratio (p=0.90).
  • Patients in the lowest iron status tertile showed a trend towards presenting with more acute coronary syndromes and more severe lesion characteristics.

Conclusions:

  • The study found no association between body iron status and the incidence of major adverse cardiac events in patients after coronary stenting.
  • Iron status, as measured by the sTfR/ferritin ratio, was not found to be a predictor of angiographic coronary restenosis.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...